Bromhexine hydrochloride composition freeze-dried powder for injection

A technology of bromhexine hydrochloride and freeze-dried powder injection, which is applied in the field of medicine and medicine manufacturing, can solve the problems of high risk of clinical use and acute renal failure, and achieve the goal of avoiding renal failure, enhancing solubility and high stability Effect
CN103565758AInactive Publication Date: 2014-02-12HAINAN WEI KANG PHARMA QIANSHAN
1 Cites 2 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
HAINAN WEI KANG PHARMA QIANSHAN
Publication Date
2014-02-12
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention provides bromhexine hydrochloride composition freeze-dried powder for injection, which relates to the field of medicines and medicine manufacturing technology. The bromhexine hydrochloride composition freeze-dried powder for injection comprises the following raw material components in parts by weight: 1 part of bromhexine hydrochloride, 0.5-1.3 parts of chitosan nanoparticles and 5-10 parts of injection water. The bromhexine hydrochloride composition freeze-dried powder for injection provided by the invention has the advantages that: 1) the chitosan nanoparticles replace mannitol to serve as a skeleton agent of the freeze-dried powder for injection, the obtained product is good in shape, high in stability and capable of avoiding a kidney failure risk caused by clinic use of the mannitol; 2) the bromhexine hydrochloride is slightly soluble in water, the chitosan nanoparticles can also be used as a cosolvent of the hydrochloride bromhexine to improve the solubleness of the hydrochloride bromhexine and facilitate industrial production and clinic use; and 3) the chitosan nanoparticles have certain antibacterial activity, when being clinically used with the hydrochloride bromhexine, the chitosan nanoparticles can cooperatively treat respiratory tract infection accompanied with a symptom that viscous sputum is unlikely to expectorate caused by sensitive bacteria.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field:

[0001] The invention relates to the technical field of medicine and medicine manufacture, in particular to a bromhexine hydrochloride composition freeze-dried powder for injection. Background technique:

[0002] Bromhexine hydrochloride, the chemical name is N-(2-amino-3,5-dibromobenzyl)-N-methylcyclohexylamine hydrochloride, very slightly soluble in water and ethanol, soluble in hot ethanol, insoluble In acetone, chloroform, odorless, tasteless. Its chemical structural formula is shown in the following formula. This product was first synthesized by Keck in 1963 and listed in 1965. my country began to produce it in 1973. It was first recorded in the 1977 edition of "Chinese Pharmacopoeia", and the name is bromhexylamine hydrochloride; "Chinese Pharmacopoeia" The 1985 version was renamed bromhexine hydrochloride.

[0003] This strain is a new type of mucus-dissolving expectorant synthesized from the active ingredient fenacine proposed in the medicinal plant ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More